The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2010 Jun 22

PMID 20560994

Citations 49

Authors

Robert A Mitchell

Nathan Herrmann

Krista L Lanctot

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is characterized by a number of serious and debilitating behavioral and psychological symptoms of dementia (BPSD). The most common of these BPSD is apathy, which represents a major source of morbidity and premature institutionalization in the AD population. Many studies have identified discrete changes to the dopaminergic (DAergic) system in patients with AD. The DAergic system is closely related to the brain reward system (BRS) and some studies have suggested that dysfunction in the DAergic system may account for symptoms of apathy in the AD population.

Method: Changes to the dopamine (DA) system in AD will be reviewed, and evidence supporting the involvement of the DAergic system in the development of apathy will be examined. Additionally, some pharmacological interventions with DA activity have been identified. The utility of these treatments in the AD population will be reviewed, with a focus on apathy as an outcome.

Results: Evidence presented in this review suggests that DA dysfunction in discrete brain areas is an important correlate of apathy in AD and that the DAergic system may be a rational target for pharmacological treatment of apathy.

Citing Articles

Dopaminergic deficits along the spectrum of Alzheimer's disease.

Pilotto A, Galli A, Sala A, Caminiti S, Presotto L, Liguori C Mol Psychiatry. 2025; .

PMID: 39890920 DOI: 10.1038/s41380-025-02913-5.

The neural basis of neuropsychiatric symptoms in Alzheimer's disease.

Zhang N, Zhang S, Zhang L, Tao H, Zhang G Front Aging Neurosci. 2024; 16:1487875.

PMID: 39703925 PMC: 11655510. DOI: 10.3389/fnagi.2024.1487875.

Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.

Saggu S, Bai A, Aida M, Rehman H, Pless A, Ware D Geroscience. 2024; 47(1):457-482.

PMID: 39331291 PMC: 11872848. DOI: 10.1007/s11357-024-01359-x.

The dopaminergic system and Alzheimer's disease.

Zhang Y, Liang Y, Gu Y Neural Regen Res. 2024; 20(9):2495-2512.

PMID: 39314145 PMC: 11801300. DOI: 10.4103/NRR.NRR-D-24-00230.

Neurochemical organization of cortical proteinopathy and neurophysiology along the Alzheimer's disease continuum.

Wiesman A, Gallego-Rudolf J, Villeneuve S, Baillet S, Wilson T Alzheimers Dement. 2024; 20(9):6316-6331.

PMID: 39001629 PMC: 11497661. DOI: 10.1002/alz.14110.

References

Huey E, Garcia C, Wassermann E, Tierney M, Grafman J . Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2009; 69(12):1981-2. PMC: 4489562. DOI: 10.4088/jcp.v69n1219a. View

Winblad B, Poritis N . Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 2000; 14(2):135-46. DOI: 10.1002/(sici)1099-1166(199902)14:2<135::aid-gps906>3.0.co;2-0. View

Starkstein S, Petracca G, Chemerinski E, Kremer J . Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry. 2001; 158(6):872-7. DOI: 10.1176/appi.ajp.158.6.872. View

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E . A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57(4):613-20. DOI: 10.1212/wnl.57.4.613. View

Clemens J, Fuller R . Differences in the effects of amphetamine and methylphenidate on brain dopamine turnover and serum prolactin concentration in reserpine-treated rats. Life Sci. 1979; 24(22):2077-81. DOI: 10.1016/0024-3205(79)90081-x. View

Mitchell S, Teno J, Kiely D, Shaffer M, Jones R, Prigerson H . The clinical course of advanced dementia. N Engl J Med. 2009; 361(16):1529-38. PMC: 2778850. DOI: 10.1056/NEJMoa0902234. View

Banerjee S, Murray J, Foley B, Atkins L, Schneider J, Mann A . Predictors of institutionalisation in people with dementia. J Neurol Neurosurg Psychiatry. 2003; 74(9):1315-6. PMC: 1738636. DOI: 10.1136/jnnp.74.9.1315. View

Debette S, Kozlowski O, Steinling M, Rousseaux M . Levodopa and bromocriptine in hypoxic brain injury. J Neurol. 2003; 249(12):1678-82. DOI: 10.1007/s00415-002-0903-1. View

Hill H, HAERTZEN C, WOLBACH Jr A, MINER E . THE ADDICTION RESEARCH CENTER INVENTORY: STANDARDIZATION OF SCALES WHICH EVALUATE SUBJECTIVE EFFECTS OF MORPHINE, AMPHETAMINE, PENTOBARBITAL, ALCOHOL, LSD-25, PYRAHEXYL AND CHLORPROMAZINE. Psychopharmacologia. 1963; 4:167-83. DOI: 10.1007/BF02584089. View

10.

Unis A, Dawson T, Gehlert D, Wamsley J . Autoradiographic localization of [3H]methylphenidate binding sites in rat brain. Eur J Pharmacol. 1985; 113(1):155-7. DOI: 10.1016/0014-2999(85)90364-4. View

11.

Tremblay L, Naranjo C, Graham S, Herrmann N, Mayberg H, Hevenor S . Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry. 2005; 62(11):1228-36. DOI: 10.1001/archpsyc.62.11.1228. View

12.

Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S . Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009; 73(21):1746-51. DOI: 10.1212/WNL.0b013e3181c34b34. View

13.

Migneco O, Benoit M, Koulibaly P, Dygai I, Bertogliati C, Desvignes P . Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients. Neuroimage. 2001; 13(5):896-902. DOI: 10.1006/nimg.2000.0741. View

14.

Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer E . Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol. 1995; 47(2):368-73. View

15.

Portet F, Scarmeas N, Cosentino S, Helzner E, Stern Y . Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol. 2009; 66(9):1120-6. PMC: 2896248. DOI: 10.1001/archneurol.2009.196. View

16.

Pritchard A, Pritchard C, Bentham P, Lendon C . Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord. 2008; 26(3):257-60. DOI: 10.1159/000160958. View

17.

Starkstein S, Merello M, Brockman S, Bruce D, Petracca G, Power B . Apathy predicts more severe parkinsonism in Alzheimer's disease. Am J Geriatr Psychiatry. 2009; 17(4):291-8. DOI: 10.1097/jgp.0b013e31818a0e35. View

18.

Reeves S, Bench C, Howard R . Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry. 2002; 17(4):359-70. DOI: 10.1002/gps.606. View

19.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H . Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14):1333-41. DOI: 10.1056/NEJMoa013128. View

20.

Padala P, Burke W, Shostrom V, Bhatia S, Wengel S, Potter J . Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010; 18(4):371-4. DOI: 10.1097/JGP.0b013e3181cabcf6. View